The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial
Open accessAbstract
BACKGROUND Early cognitive intervention is the only routine therapeutic approach used for amelioration of intellectual deficits in individuals with Down's syndrome, but its effects are limited. We hypothesised that administration of a green tea extract containing epigallocatechin-3-gallate (EGCG) would improve the effects of non-pharmacological cognitive rehabilitation in young adults with Down's syndrome. METHODS We enrolled adults (aged 16-34 years) with Down's syndrome from outpatient settings in Catalonia, Spain, with any of the Down's syndrome genetic variations (trisomy 21, partial trisomy, mosaic, or translocation) in a double-blind, placebo-controlled, phase 2, single centre trial (TESDAD). Participants were randomly assigned at the IMIM-Hospital del Mar Medical Research Institute to receive EGCG (9 mg/kg per day) or placebo and cognitive training for 12 months. We followed up participants for 6 months after treatment discontinuation. We randomly assigned participants using random-number tables and balanced allocation by sex and intellectual quotient. Participants, families, and researchers assessing the participants were masked to treatment allocation. The primary endpoint was cognitive improvement assessed by neuropsychologists with a battery of cognitive tests for episodic memory, executive function, and functional measurements. Analysis was on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT01699711. FINDINGS The study was done between June 5, 2012, and June 6, 2014. 84 of 87 participants with Down's syndrome were included in the intention-to-treat analysis at 12 months (43 in the EGCG and cognitive training group and 41 in the placebo and cognitive training group). Differences between the groups were not significant on 13 of 15 tests in the TESDAD battery and eight of nine adaptive skills in the Adaptive Behavior Assessment System II (ABAS-II). At 12 months, participants treated with EGCG and cognitive training had significantly higher scores in visual recognition memory (Pattern Recognition Memory test immediate recall, adjusted mean difference: 6·23 percentage points [95% CI 0·31 to 12·14], p=0·039; d 0·4 [0·05 to 0·84]), inhibitory control (Cats and Dogs total score, adjusted mean difference: 0·48 [0·02 to 0·93], p=0·041; d 0·28 [0·19 to 0·74]; Cats and Dogs total response time, adjusted mean difference: -4·58 s [-8·54 to -0·62], p=0·024; d -0·27 [-0·72 to -0·20]), and adaptive behaviour (ABAS-II functional academics score, adjusted mean difference: 5·49 [2·13 to 8·86], p=0·002; d 0·39 [-0·06 to 0·84]). No differences were noted in adverse effects between the two treatment groups. INTERPRETATION EGCG and cognitive training for 12 months was significantly more effective than placebo and cognitive training at improving visual recognition memory, inhibitory control, and adaptive behaviour. Phase 3 trials with a larger population of individuals with Down's syndrome will be needed to assess and confirm the long-term efficacy of EGCG and cognitive training. FUNDING Jérôme Lejeune Foundation, Instituto de Salud Carlos III FEDER, MINECO, Generalitat de Catalunya.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369
Metabolism of Green Tea Catechins: An Overview
Yong Feng, W. (2006) · Current Drug Metabolism · doi:10.2174/138920006778520552 · Cited by 301
De la Torre, R., De Sola, S., Pons, M., Duchon, A., de Lagran, M. M., Farré, M., Fitó, M., Benejam, B., Langohr, K., Rodriguez, J., et al. (2014) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201300325 · Cited by 286
Self-citationDown syndrome: the brain in trisomic mode
Dierssen, M. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3314 · Cited by 274
Self-citationGreen Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A
Guedj, F., Sébrié, C., Rivals, I., Ledru, A., Paly, E., Bizot, J. C., Smith, D., Rubin, E., Gillet, B., Arbones, M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004606 · Cited by 216
Self-citationLin, L.-C., Wang, M.-N., Tseng, T.-Y., Sung, & Tsai, T.-H. (2007) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf062816a · Cited by 211
Costanzo, F., Varuzza, C., Menghini, D., Addona, F., Gianesini, T., & Vicari, S. (2013) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2013.01.024 · Cited by 200
The mechanisms of action of flavonoids in the brain: Direct versus indirect effects
Rendeiro, C., Rhodes, J. S., & Spencer, J. P. E. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.08.002 · Cited by 178
Distinct roles for medial temporal lobe structures in memory for objects and their locationsPreprint
Buffalo, E. A., Bellgowan, P. S. F., & Martin, A. D. (2006) · Learning & Memory · doi:10.1101/lm.251906 · Cited by 140
A Longitudinal Study of Children with Down Syndrome Who Experienced Early Intervention Programming
Connolly, B. H., Morgan, S. B., Russell, F. F., & Fulliton, W. L. (1993) · Physical Therapy · doi:10.1093/ptj/73.3.170 · Cited by 123
Cited by
Antonarakis, S. E., Skotko, B. G., Rafii, M. S., Strydom, A., Pape, S. E., Bianchi, D. W., Sherman, S. L., & Reeves, R. H. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0143-7 · Cited by 964
Nutritional psychiatry: Towards improving mental health by what you eat
Adan, R. A. H., van der Beek, E. M., Buitelaar, J. K., Cryan, J. F., Hebebrand, J., Higgs, S., Schellekens, H., & Dickson, S. L. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.10.011 · Cited by 454
The safety of green tea and green tea extract consumption in adults – Results of a systematic review
Hu, J., Webster, D., Cao, J., & Shao, A. (2018) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2018.03.019 · Cited by 405
Cano, A., Ettcheto, M., Chang, J.-H., Barroso, E., Espina, M., Kühne, B. A., Barenys, M., Auladell, C., Folch, J., Souto, E. B., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.03.010 · Cited by 337
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
Metadata
- Authors
- de la Torre, R., de Sola, S., Hernandez, G., Farré, M., Pujol, J., Rodriguez, J., Espadaler, J. M., Langohr, K., Cuenca-Royo, A., Principe, A., Xicota, L., Janel, N., Catuara-Solarz, S., Sanchez-Benavides, G., Bléhaut, H., Dueñas-Espín, I., del Hoyo, L., Benejam, B., Blanco-Hinojo, L., Videla, S., Fitó, M., Delabar, J. M., & Dierssen, M.
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 15
- Issue
- 8
- Pages
- 801-810
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W2413465592
- Cited by
- 289
- References
- 29
- FWCI
- 26.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial. https://app.cochat.ai/papers/10.1016/s1474-4422(16)30034-5
- The paper
- de la Torre, R., de Sola, S., Hernandez, G., Farré, M., Pujol, J., Rodriguez, J., Espadaler, J. M., Langohr, K., Cuenca-Royo, A., Principe, A., Xicota, L., Janel, N., Catuara-Solarz, S., Sanchez-Benavides, G., Bléhaut, H., Dueñas-Espín, I., del Hoyo, L., Benejam, B., Blanco-Hinojo, L., . . . Dierssen, M. (2016). Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(16)30034-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.